BioMarin Pharmaceutical (BMRN) Competitors $65.86 +2.31 (+3.63%) Closing price 02/12/2025 04:00 PM EasternExtended Trading$64.59 -1.27 (-1.92%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BMRN vs. ALNY, BIIB, UTHR, INCY, NBIX, EXAS, EXEL, RGEN, MDGL, and HALOShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk. Does the MarketBeat Community favor ALNY or BMRN? BioMarin Pharmaceutical received 427 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.20% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.55% of users gave BioMarin Pharmaceutical an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes114076.20% Underperform Votes35623.80% BioMarin PharmaceuticalOutperform Votes156774.55% Underperform Votes53525.45% Do institutionals & insiders believe in ALNY or BMRN? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, ALNY or BMRN? Alnylam Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Is ALNY or BMRN more profitable? BioMarin Pharmaceutical has a net margin of 11.71% compared to Alnylam Pharmaceuticals' net margin of -15.86%. BioMarin Pharmaceutical's return on equity of 8.53% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-15.86% N/A -8.38% BioMarin Pharmaceutical 11.71%8.53%6.40% Does the media refer more to ALNY or BMRN? In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 15 mentions for BioMarin Pharmaceutical and 12 mentions for Alnylam Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.95 beat Alnylam Pharmaceuticals' score of 0.65 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ALNY or BMRN? Alnylam Pharmaceuticals currently has a consensus target price of $298.61, indicating a potential upside of 12.28%. BioMarin Pharmaceutical has a consensus target price of $94.20, indicating a potential upside of 43.03%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72BioMarin Pharmaceutical 0 Sell rating(s) 7 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.74 Which has higher valuation and earnings, ALNY or BMRN? BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$1.83B18.76-$440.24M-$2.62-101.51BioMarin Pharmaceutical$2.42B5.19$167.65M$1.6739.44 SummaryBioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.26B$7.02B$5.78B$9.16BDividend YieldN/A2.91%5.32%4.00%P/E Ratio39.444.0155.9614.33Price / Sales5.19312.26984.6373.99Price / Cash35.9675.4646.0938.87Price / Book2.515.535.125.00Net Income$167.65M$123.50M$113.24M$222.75M7 Day Performance2.36%-3.29%-1.43%-1.01%1 Month Performance-1.69%-0.08%4.81%4.04%1 Year Performance-23.53%5.40%25.30%21.71% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9124 of 5 stars$65.86+3.6%$94.20+43.0%-25.3%$12.26B$2.42B39.443,401Analyst UpgradeNews CoverageALNYAlnylam Pharmaceuticals4.4597 of 5 stars$273.67-0.9%$298.61+9.1%+57.1%$35.30B$2.09B-104.452,100Analyst ForecastShort Interest ↓BIIBBiogen4.7243 of 5 stars$142.50+0.8%$228.80+60.6%-45.5%$20.77B$9.61B12.877,570Earnings ReportAnalyst ForecastOptions VolumeNews CoverageUTHRUnited Therapeutics4.463 of 5 stars$345.38-0.7%$382.08+10.6%+71.4%$15.42B$2.76B15.171,168Insider TradeAnalyst RevisionINCYIncyte4.5136 of 5 stars$68.30-7.9%$75.71+10.8%+19.4%$13.16B$3.70B487.892,524Earnings ReportAnalyst ForecastShort Interest ↑NBIXNeurocrine Biosciences4.9589 of 5 stars$118.80-3.1%$168.35+41.7%-10.2%$12.03B$2.36B36.111,400Earnings ReportAnalyst ForecastInsider TradeShort Interest ↓EXASExact Sciences4.7968 of 5 stars$52.34-2.2%$72.76+39.0%-18.9%$9.69B$2.69B-44.736,600Upcoming EarningsPositive NewsEXELExelixis4.9339 of 5 stars$33.50+0.1%$36.06+7.7%+60.9%$9.57B$1.83B21.471,310Earnings ReportAnalyst DowngradeShort Interest ↓Analyst RevisionNews CoverageRGENRepligen4.1975 of 5 stars$153.94-1.4%$186.00+20.8%-29.2%$8.63B$638.76M-416.041,783Analyst ForecastNews CoveragePositive NewsMDGLMadrigal Pharmaceuticals3.5819 of 5 stars$337.57+1.5%$351.67+4.2%+57.2%$7.36B$76.81M-13.4690Analyst RevisionHALOHalozyme Therapeutics4.3721 of 5 stars$57.34+0.4%$60.89+6.2%+62.8%$7.29B$947.36M18.99390Upcoming EarningsAnalyst Revision Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXAS Competitors EXEL Competitors RGEN Competitors MDGL Competitors HALO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BMRN) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.